- Meeting abstract
- Open Access
Molecular target therapy – towards curative regimen: a 20-year experience in the treatment of acute promyelocytic leukemia (APL) in the Shanghai Institute of Hematology
© Shen; licensee BioMed Central Ltd. 2009
- Published: 26 June 2009
- Acute Myeloid Leukemia
- Acute Leukemia
- Acute Promyelocytic Leukemia
- Acute Promyelocytic Leukemia Cell
- Acute Promyelocytic Leukemia Patient
Since the first description of acute promyelocytic leukemia (APL) in 1957 as the most malignant form of acute leukemia, several developments have paved the way to make this disease the most curable leukemia in adults and change the paradigm of cancer treatment. Therapy of APL was pioneered by Bernard et al in 1973 demonstrating a striking sensitivity to daunorubicin, probably related to significantly lower P-glycoprotein expression observed in APL cells compared to other subtypes of acute myeloid leukemia (AML).
The incorporation of ATRA, a noncytotoxic differentiating agent that is regarded as the first differentiation therapy has changed dramatically the management, outcome, and prognosis of APL.
ATRA was first introduced to clinical use for the treatment of APL in 1986. Since then, randomized studies in many centers around the world document a rising CR rate, a decrease in severe adverse effects, and a prolongation of remission duration. ATRA combined with anthracycline-based chemotherapy can achieve CR in 90–95% of patients with APL and cure the disease in 70–75% of the cases. Combination therapy with ATRA and chemotherapeutic agents should now be considered as a standard treatment of APL.
Over the last decade, tremendous efforts have been made to elucidate the molecular genesis of APL, as well as the mechanism of action of ATRA. The mechanism of action of ATRA can be summarized as follows: 1. The binding of ATRA to RAR receptors causes degradation of PML-RARα protein through the ubiquitin-proteosome and caspase system, leading to restoration of terminal differentiation of promyelocytes; 2. Exposure of APL cells to ATRA in vitro or in vivo induces relocalization of PML and restores the normal structure of PODs; and 3. Under the action of ATRA, CoR is dissociated from the repressive complex, whereas CoA (coactivator) is recruited to the complex. As a result, the repression of transcriptional activation of target genes is relieved and the differentiation of promyelocytes is restored.
Treatment of APL by arsenic compounds represents a successful example of apoptosis induction therapy of acute leukemia. As2O3 exerts dual effects on APL cells. Studies in vitro with NB4 cells showed that a higher concentration of As2O3 (0.5–1.0 μM) induced apoptosis with typical morphological changes, DNA laddering on agarose gel electrophoresis, appearance of an apoptotic peak on flow cytometric analysis, and increased expression of annexin V on the cell surface membrane. At lower concentrations, As2O3 can induce APL cells to partially differentiate along the granulocytic pathway.
Synergistic effect of ATRA and As2O3 was confirmed by several research works in vivo and in vitro. The first clinical trial was completed by SIH in 2001. CR rate was same as ATRA or As2O3 alone, but the median day to CR was very short, only 26 days, and OS and DFS were much better than ATRA or As2O3 alone. Now timing and dose of As2O3 combined with ATRA in newly diagnosed APL patients need to be confirmed.
Recently, several genetic and phenotypic characteristics of acute promyelocytic leukemia (APL) blasts have been demonstrated. These include the PML/RARα fusion and the transcription co-repressor complex recruited at the promoter of target genes by the hybrid protein, the intense and homogeneous expression of the CD33 antigen, and absence of multidrug resistance-related phenotype, a frequently mutated and constitutively activated FLT3 receptor. Such genotypic and phenotypic features are targeted by agents currently in use in front-line therapy or at relapse (i.e., retinoids, As2O3, anthracyclines and anti-CD33 monoclonal antibodies), and by novel agents that many find a place in future treatments such as histone deacetylase and FLT3 inhibitors.
This article is published under license to BioMed Central Ltd.